Business
Results for the year ended 30 April 2021
Results for the year ended 30 April 2021.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 6515Q\n Scancell Holdings Plc\n 29 October 2021\n \n \n \n \n 29 October 2021\n \n \n \n \n \n \n \n \n Scancell Holdings plc\n \n \n (\"Scancell\" or the \"Company\")\n \n \n \n \n \n Results for the year ended 30 April 2021\n \n \n \n \n \n Strong progress during transformative period for the Company; raised £48 million to accelerate clinical progress of vaccine and antibody platforms\n \n \n \n \n \n \n \n \n Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces its final audited financial results for the year ended 30 April 2021 as well as a business update.\n \n \n \n \n \n Highlights (including post period):\n \n \n \n \n \n Operational:\n \n \n \n \n \n · \n Significant progress made with vaccine programmes\n \n \n \n \n \n o \n Modi-1, lead Moditope® candidate, moves into clinical development\n \n \n § \n Post period approval by the UK's Medicines and Healthcare Products Regulatory Authority (MHRA) of the clinical trial application (CTA) to initiate the first-in-human Phase 1/2 clinical study\n \n \n § \n Good Manufacturing Practice (GMP) drug manufacture advanced and formal regulatory-compliant toxicity studies completed\n \n \n § \n Publication of peer-reviewed paper in the Journal for ImmunoTherapy of Cancer highlighting the potential of Modi-1 for hard-to-treat cancers\n \n \n \n \n \n o \n First subject dosed in Scancell's COVID-19 vaccine Phase 1 clinical trial (COVIDITY)\n \n \n \n § \n Phase 1 trial approval from the South African Health Products Regulatory Authority post period\n \n \n § \n PharmaJet Needle-free Injection Systems selected post period to administer the Company's two SARS-CoV-2 vaccine candidates\n \n \n § \n Manufacturing agreement with Cobra Biologics including GMP production of plasmid DNA\n \n \n § \n Secured c.£2m of funding from Innovate UK to fund the Phase 1 trial \n \n \n \n \n \n o \n Post-pandemic restart for SCIB1 Phase 2 combination trial with Keytruda® in patients with late-stage melanoma with four clinical centres operational and actively screening patients\n \n \n \n \n \n · \n Advancing antibody platform\n \n \n \n \n \n o \n Developing unique, rich pi...